January 3, 2022
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.
August 31, 2021
As part of the NIH-sponsored ACTIV-2 clinical trial for COVID-19 outpatients, preliminary data revealed that a new combination monoclonal antibody treatment reduced hospitalizations and death by 78 percent in high-risk patients. ACTIV-2 vice chair David Wohl, MD, leads monoclonal treatment for UNC Health.
May 17, 2021
Project Alive, a non-profit organization dedicated to finding a cure for Hunter syndrome, has surpassed its goal of raising $2.5 million dollars for a gene therapy clinical trial to be led by UNC School of Medicine researcher Joseph Muenzer, MD, PhD.
October 5, 2020
The first investigational agent to be evaluated by ACTIV-2 is LY3819253, an experimental monoclonal antibody treatment made by Lilly Research Laboratories in partnership with AbCellera Biologics.
March 20, 2019
ZULRESSO, developed by Sage Therapeutics, is the first and only treatment specifically indicated to treat postpartum depression in women. UNC School of Medicine’s Samantha Meltzer-Brody, MD, MPH, was the principal investigator for three clinical trials showing rapid-reduction in depressive symptoms, and says the approval marks a major step forward in women’s healthcare.
April 2, 2013
Patient Jessica Riley was referred to the UNC Wound Healing Center, part of the UNC Center for Heart and Vascular Care, for her venous leg ulcer and entered a clinical trial led by William Marston, MD **Graphic images included**